Pig B cell proliferation induction ligand protein as well as preparation method and application thereof

By removing the transmembrane region of APRIL protein and expressing it in E. coli, the unclear role of ligand protein in pig B cell proliferation in pig epidemic diarrhea virus infection was solved, and the survival and immune response of pig B cells were studied. It provides a scientific basis for the development of more effective vaccines.

CN118909083APending Publication Date: 2024-11-08JIANGSU ACAD OF AGRI SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411030447.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The lack of effective research on ligand proteins in the prior art, especially in the infection and immune response of porcine epidemic diarrhea virus (PEDV) is unclear, and the immune protection effect of the vaccine is affected by the variant strain, which is urgently needed. Develop safer and more efficient vaccines.

Method used

By predicting the secondary structure and functional domain of APRIL protein, the recombinant vector was constructed after removing the transmembrane region, and the porcine B cell proliferation-induced ligand protein was expressed and purified in the E. coli expression system, ensuring its functionality and being used to study its in vivo mucosum Role in immune response.

Benefits of technology

Successfully obtaining recombinant proteins that remove transmembrane regions, inhibit the proliferation of IgM+B cells, and at the same time ensure the survival of B cells, has important scientific significance and research value, and provides an important scientific basis for further research on PEDV infection and immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909083A_ABST
    Figure CN118909083A_ABST
Patent Text Reader

Abstract

The invention discloses a pig B cell proliferation inducing ligand protein as well as a preparation method and application thereof, and belongs to the field of genetic engineering. After a secondary structure, a functional domain and a transmembrane region of a proliferation induction ligand protein are predicted, a recombinant protein amino acid sequence without the transmembrane region is obtained, then a recombinant vector for expressing the recombinant protein is constructed and expressed and purified in an escherichia coli expression system, and it is identified that the recombinant protein can guarantee the survival of pig B cells, so that the recombinant protein can be used for preparing the pig B cells. The method has important scientific significance and value in the aspects of researching the action mechanism of the proliferation-induced ligand protein on porcine epidemic diarrhea virus infection, preparing mucosal vaccines for preventing and controlling porcine enterovirus diseases and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of genetic engineering, and in particular to a porcine B cell proliferation inducing ligand protein and a preparation method and application thereof. Background Art

[0002] Porcine enterovirus diseases cause huge economic losses to the development of the pig industry, mainly including transmissible gastroenteritis (TGE), porcine epidemic diarrhea (PED), porcine delta coronavirus (PDCo) and porcine acute diarrhea syndrome coronavirus (SADS-Co). Among them, porcine epidemic diarrhea (PED) is a common porcine enterovirus disease caused by porcine epidemic diarrhea virus (PEDV). It is a highly contact enteric infectious disease that is mainly infected through the oral and nasal route. It can colonize and multiply in large numbers in intestinal epithelial cells, causing damage and shedding of intestinal epithelial cells and intestinal villi, thereby leading to severe diarrhea symptoms and dehydration and death of pigs. It is one of the common diseases that has long endangered the healthy development of the pig industry. Vaccination is currently the most economical and effective measure to prevent PED, but due to the continuous emergence of PEDV variants, the immune protection effect of the vaccine is poor. Therefore, it is urgent to develop safer and more efficient vaccines to prevent PED.

[0003] Studies have shown that efficient stimulation of mucosal immunity is crucial for the prevention and treatment of PED. Research on pig mucosal immune response is of great significance for the design of mucosal vaccines for the prevention and control of porcine enterovirus diseases. Vaccines mainly work through humoral immunity and cellular immunity. There are few studies on pig mucosal immune response, and the role of various cytokines involved in pig mucosal immune response is still unclear. It is known that cytokines are important proteins that regulate cell functions and are involved in biological processes such as immune response, cell proliferation and differentiation. With the development of biotechnology, new cytokines are constantly being discovered, and the understanding of their mechanism of action and biological functions is also deepening.

[0004] Proliferation-inducing ligand (APRIL) is a member of the tumor necrosis factor family. In human medical research, APRIL was found to be involved in B cell maturation and stimulation of plasma cell formation. However, there is no research on the expression and preparation of porcine APRIL protein, and its role in porcine mucosal immune response is still unclear. Although there is no research on the effect of APRIL on PEDV, research results show that host cytokines may play an important role in the molecular mechanism of PEDV infection and immune response. In the future, there may be more studies revealing the potential role of APRIL in PEDV infection. Based on the above problems, the problem to be solved by the present invention is to prepare porcine B cell proliferation-inducing ligand and identify its basic functions. Summary of the invention

[0005] The purpose of the present invention is to provide a porcine B cell proliferation inducing ligand protein and a preparation method and application thereof, so as to solve the problems existing in the above-mentioned prior art. The present invention removes the transmembrane region of the APRIL protein to obtain the amino acid sequence of the APRIL recombinant protein, then constructs a recombinant vector, expresses and purifies it in an Escherichia coli expression system, and it is identified that the recombinant protein can ensure the survival of porcine B cells.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The invention provides a porcine B cell proliferation inducing ligand protein, the amino acid sequence of which is shown in SEQ ID NO:1.

[0008] The present invention also provides a biomaterial related to a porcine B cell proliferation inducing ligand protein, including any one of the following:

[0009] (1) A nucleic acid molecule encoding the porcine B cell proliferation-inducing ligand protein according to claim 1;

[0010] (2) An expression cassette, recombinant vector or recombinant bacteria containing the nucleic acid molecule.

[0011] Preferably, the sequence of the nucleic acid molecule is as shown in SEQ ID NO:2.

[0012] The present invention also provides a method for preparing a porcine B cell proliferation inducing ligand protein, comprising the following steps:

[0013] Obtaining a gene sequence encoding a porcine B cell proliferation-inducing ligand protein, and constructing a recombinant vector with the gene sequence and an expression vector;

[0014] Expressing the recombinant vector in a recipient bacterium to obtain a recombinant bacterium;

[0015] The recombinant bacteria are induced to culture, and the porcine B cell proliferation inducing ligand protein is separated and purified from the bacteria.

[0016] Preferably, the gene sequence is as shown in SEQ ID NO: 2:

[0017] .

[0018] Preferably, the recipient bacteria is Escherichia coli.

[0019] Preferably, the induction culture conditions of the recombinant bacteria are: induction with isopropylthiogalactoside (IPTG) at an induction concentration of 0.2 mmol / L-1.0 mmol / L; culturing at 16° C. and 200 rpm for 8-24 hours and harvesting the bacteria.

[0020] Preferably, the separation and purification comprises the following steps:

[0021] The collected bacteria were resuspended, disrupted by ultrasound, and the supernatant was collected;

[0022] After filtering the supernatant, a nickel column was added, and eluted with 20 mM-500 mM imidazole eluent, and eluents of different concentrations were collected.

[0023] The present invention also provides the use of the porcine B cell proliferation inducing ligand protein in any of the following items:

[0024] (1) Application in the preparation of products for improving the survival rate of pig B cells;

[0025] (2) Application in studying the mechanism of action of porcine mucosal immune response;

[0026] (3) Application in studying the mechanism of action of porcine B cell proliferation-inducing ligand protein in porcine epidemic diarrhea virus infection.

[0027] The present invention discloses the following technical effects:

[0028] The present invention predicts the secondary structure, functional domain and transmembrane region of the proliferation-inducing ligand protein, and obtains the amino acid sequence of the recombinant protein without the transmembrane region. Based on genetic engineering technology, the present invention constructs a recombinant vector for expressing the proliferation-inducing ligand recombinant protein without the transmembrane region, and expresses and purifies it in an Escherichia coli expression system. It is identified that the proliferation-inducing ligand recombinant protein without the transmembrane region inhibits IgM + The proliferation of B cells is inhibited, but the survival of B cells is effectively guaranteed, which has important scientific significance and research value for further studying the role of proliferation-inducing ligands in the infection and immune response of PEDV. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0030] Figure 1 is the secondary structure of APRIL protein;

[0031] Figure 2 It is the functional domain of APRIL protein;

[0032] Figure 3 The results of double enzyme digestion electrophoresis of recombinant plasmids; M: KB Ladder, 1: pCold-SUMO plasmid, 2: pCold-SUMO-APRIL plasmid after digestion with ECoRI and HindIII;

[0033] Figure 4 Schematic diagram of the construction of pCold-SUMO-APRIL plasmid;

[0034] Figure 5 The results of screening the inducible expression conditions of soluble pCold-SUMO-APRIL expressed in E. coli BL21 (DE3); A: screening of different IPTG, B: screening of different OD values, C: screening of different sampling times; where M: protein marker, s: supernatant after ultrasound, p: precipitate after ultrasound;

[0035] Figure 6 The purification and identification results of the recombinant protein; A is the SDS-PAGE identification result of the purified recombinant protein, lane 1: protein marker, lane 2: whole bacteria after induction, lane 3: supernatant after induction, lane 4: precipitate after induction, lane 5: flow-through, lanes 6-10: 300mM elution collection solution, lanes 11-15: 500mM elution collection solution, lane 16: dialyzed concentrated protein; B is the Western blot identification result of the purified pCold-SUMO-APRIL, lane 1: protein marker, lane 2: empty load, lane 3: purified protein; C is the purified protein coated with different concentrations and reacted with anti-His tag antibodies to construct different protein concentration-His reaction curves;

[0036] Figure 7 The results of functional identification of the recombinant protein; A: The effect of different concentrations of APRIL protein on the expression of BCMA and CD40, B: The effect of different concentrations of APRIL protein on the proliferation and survival of B cells. DETAILED DESCRIPTION

[0037] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0038] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0039] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0040] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0041] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0042] Example 1

[0043] 1. Materials

[0044] (1) Experimental Materials

[0045] pCold-SUMO and pCold-SUMO-APRIL recombinant expression plasmids were preserved by the Veterinary Research Institute of Jiangsu Academy of Agricultural Sciences. Escherichia coli competent BL21 was purchased from Quanshijin Biotechnology Co., Ltd.; HisTrap HP was purchased from Cytiva; 10kd dialysis bag and dialysis clip, ampicillin, and red blood cell lysis buffer were purchased from Solarbio; porcine peripheral blood lymphocyte separation fluid kit was purchased from Jinshi Haoyang Biological Products Technology Co., Ltd.; BCA protein concentration determination kit was purchased from Biyuntian; cell filter (40μm / 100μm cell strainer) was purchased from Biologix; TRIzol was purchased from Takara; reverse transcriptase was purchased from Norveg; flow tube was purchased from Labre; gauze, 15mL centrifuge tube and 50mL centrifuge tube were purchased from SAINING; MACS MultiStand, MACS TMSeparator, Whole Blood Column Kit, Anti-Mouse IgG MicroBeads were purchased from Miltenyi; Anti-bovine sIgM MAb was purchased from Kingfisher Biotech; CD40 Antibody / anti-human / PE, CD269 (BCMA) Antibody, streptavidin-FITC, eBioscience TM CFSE Proliferation Dye was purchased from Invitrogen; 1640 culture medium was purchased from Yuanpei; PBS phosphate powder was purchased from Biosharp; chloroform was purchased from Keshi; isopropanol was purchased from Damao; glycerol was purchased from Komiou; ethanol was purchased from Hushi, IPTG was purchased from Biosharp; Fetal Bovine Serum was purchased from VivaCell. Fluorescence quantitative machines, flow cytometers and other instruments are all owned by the Jiangsu Academy of Agricultural Sciences, and sequencing was completed by Nanjing Qingke Biological Company.

[0046] (2) Culture medium

[0047] 1L LB medium contains 10g NaCl, 10g tryptone and 5g yeast extract.

[0048] 1L Coomassie Brilliant Blue staining solution contains 2.5g R250, 450mL methanol, 100mL glacial acetic acid and 450mL pure water.

[0049] 1L of decolorizing solution contains 100mL of glacial acetic acid, 300mL of methanol and 600mL of pure water.

[0050] 1L of coating solution (carbonate buffer) contains 1.59g Na2CO3 and 2.94g NaHCO3.

[0051] 1L Binding buffer contains 0.5M NaCl, 0.02M H2PO4.2H2O, 20mM / 100mM / 500mM imidazole, pH=7.5-8.0.

[0052] 2. Construction of truncated prokaryotic expression vector

[0053] After predicting the secondary structure, functional domain and transmembrane region of APRIL protein, the amino acid sequence without the transmembrane region was obtained, and the upstream and downstream restriction sites (KpnI, SalI) were designed according to the existing prokaryotic expression vector pCold-SUMO (purchased from Wuhan Miaoling Biotechnology Co., Ltd.) in the laboratory, and the sequence was optimized and synthesized and cloned into pCold-SUMO (GenScript Biotechnology Co., Ltd.) to construct the recombinant plasmid. The recombinant plasmid was transformed into BL21 (DE3) competent cells. Take the competent cells of Escherichia coli BL21 (DE3) and place them on ice to melt, add about 40 ng of the recombinant vector and mix evenly, and place them on ice for 20 minutes; heat shock the competent cells after adding the recombinant vector in a 42°C water bath for 90 seconds, and then transfer them to ice for 2 minutes. In the clean bench, add 600 μL LB culture medium (without resistance) to the competent cells containing the recombinant vector, and culture them at 37°C and 200 rpm for 1 hour. The cultured bacterial liquid is centrifuged at 12000 rpm for 10 minutes, the supernatant is discarded, and 100 μL of the culture liquid is retained for resuspending, and then added dropwise to the LB solid culture medium containing ampicillin resistance. Use a disposable sterile coating rod to evenly spread the culture liquid, invert it in a 37°C constant temperature incubator and culture it for 12-16 hours, pick a single colony, name it BL21 (pCold-SUMO-APRIL), and complete verification through bacterial liquid PCR, double enzyme digestion identification and sequencing.

[0054] 3. Induced expression and identification of recombinant proteins

[0055] 3.1 Screening of IPTG induction conditions

[0056] The positive strains were inoculated into LB liquid medium containing ampicillin and cultured at 37°C and 200 rpm for 6-8 hours. The culture was expanded at a volume ratio of 1:100. When the bacteria reached the logarithmic growth phase (OD 600nm ≈0.4-0.6), let stand at 16℃ for 30min, add different concentrations of IPTG (0mmol / L, 0.2mmol / L, 0.4mmol / L, 0.6mmol / L, 0.8mmol / L, 1.0mmol / L) to induce BL21(pCold-SUMO-APRIL), and culture at 16℃ for 24h to collect the bacteria. After the culture is completed, centrifuge at room temperature for 6min at 8000rpm to discard the supernatant, wash and add 1 / 2PBS to resuspend the bacteria, centrifuge, discard the supernatant, and resuspend the bacteria by 5 times concentration; place on ice water mixture, use ultrasonic crusher for ultrasonic crushing, ultrasonic power is 30%, supersonic 3s off 5s, ultrasonic 1-2min; centrifuge at 4℃, 8000rpm for 6min, collect the supernatant and precipitate of the induced strain; add 5× Loading Buffer, denature in water bath for 10min, and perform 10% SDS-PAGE analysis.

[0057] 3.2 OD value screening

[0058] The culture was expanded at a volume ratio of 1:100 and cultured at 37°C and 200 rpm for 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, and 4 h (corresponding to OD 600nm Values ​​≈ 0.196, 0.325, 0.642, 1.023, 1.337, 1.537)), the expression was induced with the optimal IPTG concentration: 0.8 mM, the bacteria were cultured at 16 °C for 24 h, the bacteria were harvested, ultrasonically disrupted, and samples were prepared for SDS-PAGE analysis.

[0059] 3.3 Selection of sampling time

[0060] When the optimal induction IPTG concentration and OD value are known, the sampling time steps are as follows: expand the culture at a volume ratio of 1:100, culture at 37°C, 200rpm for 2h, then induce with 0.8mM IPTG, culture at 16°C for 8h, 12h, 16h, 20h and 24h, respectively, harvest the bacteria, ultrasonically disrupt them, prepare samples, and perform SDS-PAGE analysis.

[0061] 4. Recombinant protein purification

[0062] When the soluble expression level of the recombinant bacteria was relatively stable, the recombinant protein was purified. After BL21 (pCold-SUMO-APRIL) induced expression, the bacteria were collected, resuspended in PBS (diluted to a concentration of 0.2 mg / mL), ultrasonically disrupted, and the supernatant was collected and filtered through a 0.45 μm filter. The nickel column and peristaltic pump were combined to pass through 5 times the column volume (5V) of 500mM Binding buffer (2.5mL / min), 5V H2O, and 5V 20mM Binding buffer in sequence. The loading flow rate was (1mL / min). Gradient elution was used, i.e., 5V 20mM Binding buffer, 5V 50mM Binding buffer, 5V 100mM Binding buffer, 5V 200mM Binding buffer, 5V 300mM Binding buffer, 5V 500mM Binding buffer, 5V 20mM Binding buffer, 5V water, and 7V 20% ethanol, collect different concentrations of eluate, prepare samples, and perform SDS-PAGE analysis. The eluted protein was dialyzed and concentrated, and then analyzed by SDS-PAGE, Western blot and ELISA. Western blot used primary His tag antibody (1:5000), secondary HRP-labeled goat anti-mouse IgG (1:5000), ELISA coated purified protein at different concentrations at 4°C overnight (4μg / mL, 2μg / mL, 1μg / mL, 0.5μg / mL, 0.25μg / mL, 0.125μg / mL, 0.063μg / mL, 0μg / mL), 5% skim milk powder was blocked at 37°C for 2h, primary His tag antibody (1:10000) at 37°C for 2h, secondary HRP-labeled goat anti-mouse IgG (1:10000) at 37°C for 1h, BCA measured protein concentration, labeled and packaged for freezing.

[0063] 5. Functional identification of recombinant protein

[0064] 5.1 Isolation of peripheral blood lymphocytes (PBMC)

[0065] Take 5mL of separation solution and put it into a 15mL centrifuge tube. Add 5mL of fresh porcine whole blood to the upper layer of separation solution. Centrifuge at 4℃ and 400g / min for 30min. Then aspirate the mononuclear cell interface layer and wash with PBS containing three antibodies (containing a mixed solution of penicillin, streptomycin and amphotericin, product number: Solebo P7630; volume ratio 1:100). Centrifuge at 4℃ and 400g / min for 10min. After washing three times, add an appropriate amount of red blood cell lysis solution and react at room temperature for 5min to terminate lysis. After centrifugation, discard the supernatant. After washing three times, use a cell counting plate to measure the cell number. 1×10 7 / mL density plate, cultured with 1640 complete medium containing 10% serum. IgM was separated by magnetic column separation + B cells were washed three times, resuspended, counted, and plated.

[0066] 5.2 Cell proliferation assay (CFSE)

[0067] The obtained lymphocytes were resuspended with 1 mL of PBS containing 0.2% serum, 1 μL of CFSE dye was added, and incubated at 37°C for 10 min. Five times the volume of 1640 medium containing 10% serum was used for ice bath for 5 min, and then centrifuged at 400 g / min at 4°C for 10 min. The supernatant was discarded, and the cells were washed with PBS containing 0.2% serum and plated. The experimental protein was added, and the medium was changed semi-quantitatively every 2-3 days. The samples were collected after 7 days, and the cell proliferation was detected by flow cytometry.

[0068] 5.3 RT-qPCR

[0069] RNA was extracted using Trizol. Trizol was added at a volume ratio of 1:1 and allowed to stand for 5 min. Chloroform was added at a volume ratio of 4:1. After vortexing and standing, stratification occurred. Then, the supernatant was transferred and isopropanol was added at a volume ratio of 1:1 and mixed until the transparent flocs disappeared. The supernatant was precipitated at -20°C for 30-60 min, and then centrifuged at 4°C and 12000 rpm for 10 min. The supernatant was discarded, and pre-cooled 75% ethanol was added. After washing twice, the supernatant was discarded, and 25 μL H2O was added for re-suspending and centrifugation to obtain total RNA. According to the reverse transcriptase and fluorescence quantitative operation instructions of Novozyme, the expression of the transcription level of downstream factors was detected by relative quantitative method, and statistical analysis was performed. The primers were synthesized by Nanjing Qingke Biological Company. The specific primer sequences are shown in Table 1.

[0070] Table 1 Fluorescence quantitative PCR primers

[0071]

[0072]

[0073] 5.4 Flow cytometry

[0074] Transfer the cell sample to a flow cytometry tube and incubate with primary antibody BCMA at 4°C in the dark. + CD40 + After incubation for 30 min, add 1 mL of PBS containing 0.2% BSA, wash and centrifuge twice, incubate with secondary antibody streptavidin-FITC at 4°C in the dark for 30 min, add 1 mL of PBS containing 0.2% BSA, wash and centrifuge twice, and detect on the flow cytometer according to the operating instructions, and process the data with Flowjo software.

[0075] 6. Results

[0076] 6.1 Construction and identification of recombinant expression plasmid

[0077] like Figure 1-Figure 2 As shown in Table 2, the results show that the APRIL protein has multiple helical and folded structures, its functional domain is located at amino acids 117-251aa, and the transmembrane region is located at 27-49aa. The amino acid sequence of the truncated APRIL protein (SEQ ID NO: 1) obtained by removing the sequence of the transmembrane region (50-251aa) is:

[0078] QQTELQTLRREVTRLQRTGGPSEKGEGDPWQNLWEQEQSPDGAEAWENGERSRRRRAVLTRKQKKKRSVLHLVPTNITSKEDSDVTELMWQPALKRGRGLE AQGYFVRVWDAGVYLLYSQVLFHDVTFTMGQVVSREGQGRQETLFRCIRSMPSNPDWAYNSCYSAGVFHLHQGDILSVVIPRARAKLSLSPHGTFLGVVKL.

[0079] like Figure 3 As shown in the figure, the constructed recombinant plasmid was successfully verified by double enzyme digestion, the band size was consistent with the expectation, and the DNA sequencing results showed that the sequence was correct. Figure 4 As shown, it shows a schematic diagram of the construction of pCold-SUMO-APRIL.

[0080] Table 2 APRIL protein structure

[0081] name Starting amino acid position End amino acid position E-value Transmembrane domain 27 49 N / A Functional domain (TNF) 117 251 0.00246

[0082] 6.2 Screening of inducible expression conditions for recombinant proteins

[0083] like Figure 5 As shown in A-C, the results showed that pCold-SUMO-APRIL 600 ≈0.5-0.6, induced by 0.8mM IPTG, cultured at 16℃, 200rpm for 24h and collected samples. The soluble form of pCold-SUMO-APRIL was expressed stably, with a size of about 40ku, which was consistent with the expected size.

[0084] 6.3 Purification and identification of recombinant protein

[0085] like Figure 6 As shown in A, the results show that the eluate obtained by eluting the protein in 500 mM eluent was dialyzed and concentrated, and the concentration measured by BCA was 0.1 mg / mL; Figure 6As shown in B, the Western blot results showed that pCold-SUMO-APRIL reacted with the anti-His tag antibody and a band appeared at 41.6 ku, which was consistent with the expected size; Figure 6 As shown in C, the ELISA identification results, pCold-SUMO-APRIL reacted with anti-His tag antibody, and the His reaction curves of different protein concentrations were constructed.

[0086] 6.4 Functional identification of recombinant proteins

[0087] like Figure 7 As shown in A, both 10 ng / mL and 100 ng / mL of APRIL protein effectively upregulated the expression of BCMA and slightly upregulated the expression of CD40. Figure 7 Middle B shows that APRIL protein inhibits IgM + It inhibits the proliferation of B cells but effectively ensures the survival of B cells.

[0088] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A porcine B cell proliferation inducing ligand protein, characterized in that: Its amino acid sequence is shown in SEQ ID NO:

1.

2. A biomaterial related to porcine B cell proliferation inducing ligand protein comprises any of the following: (1) A nucleic acid molecule encoding the porcine B cell proliferation-inducing ligand protein according to claim 1; (2) An expression cassette, recombinant vector or recombinant bacteria containing the nucleic acid molecule.

3. The biomaterial according to claim 2, characterized in that The sequence of the nucleic acid molecule is shown in SEQ ID NO:

2.

4. A method for preparing a porcine B cell proliferation inducing ligand protein, characterized in that: The following steps are involved: Obtaining a gene sequence encoding a porcine B cell proliferation-inducing ligand protein, and constructing a recombinant vector by combining the gene sequence with an expression vector; Expressing the recombinant vector in a recipient bacterium to obtain a recombinant bacterium; The recombinant bacteria are induced to culture, and the porcine B cell proliferation inducing ligand protein is separated and purified from the bacteria.

5. The preparation method according to claim 4, characterized in that: The gene sequence is shown in SEQ ID NO:

2.

6. The preparation method according to claim 4, characterized in that: The recipient bacteria is Escherichia coli.

7. The preparation method according to claim 4, characterized in that: The induction culture conditions of the recombinant bacteria are as follows: induction with isopropylthiogalactoside at an induction concentration of 0.2 mmol / L-1.0 mmol / L; culture at 16° C. and 200 rpm for 8-24 hours and harvesting the bacteria.

8. The preparation method according to claim 4, characterized in that: The separation and purification comprises the following steps: The collected bacteria were resuspended, disrupted by ultrasound, and the supernatant was collected; After filtering the supernatant, a nickel column was added, and eluted with 20 mM-500 mM imidazole eluent, and eluents of different concentrations were collected.

9. Use of the porcine B cell proliferation inducing ligand protein according to claim 1 in any of the following: (1) Application in the preparation of products for improving the survival rate of pig B cells; (2) Application in studying the mechanism of action of porcine mucosal immune response; (3) Application in studying the mechanism of action of porcine B cell proliferation-inducing ligand protein in porcine epidemic diarrhea virus infection.

Citation Information

Patent Citations

  • APPIL-a novel protein with growth effects

    CN1270632A

  • B cell activating factor (BAFF)-a proliferation inducing ligand (APRIL) dual inhibitors

    WO2023089500A1